Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald van Vollenhoven

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
Annals of the Rheumatic Diseases|June 23, 2016
Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLERonald van Vollenhoven
Nature Reviews. Rheumatology|February 1, 2019
Treat-to-target in rheumatoid arthritis - are we there yet?Ronald van Vollenhoven
Nature Reviews. Rheumatology|January 15, 2016
Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatmentRonald van Vollenhoven
Lupus Science & Medicine|February 26, 2020
String of successful trials in SLE: have we cracked the code?Ronald van Vollenhoven
Arthritis & Rheumatology (Hoboken, N.J.)|September 15, 2025
"Negative" finding supports two-hit model: comment on the article by Kroese et alRonald van Vollenhoven
Arthritis and Rheumatism|August 6, 2005
Dehydroepiandrosterone versus placebo for Sjögren's syndrome: comment on the article by Pillemer et alRonald van Vollenhoven
Lancet (London, England)|May 29, 2026
Targeting CD40 with dapirolizumab pegol: a new treatment for systemic lupus erythematosusRonald van Vollenhoven
Annals of the Rheumatic Diseases|April 30, 2013
Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examplesBernard Combe, Ronald van Vollenhoven
Lupus Science & Medicine|November 8, 2014
Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issueJill Buyon, Ronald van Vollenhoven
Clinical and Experimental Rheumatology|October 17, 2013
New drugs in systemic lupus erythematosus: when to start and when to stopMarta Mosca, Ronald van Vollenhoven
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
Annals of the Rheumatic Diseases|June 23, 2016
Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLERonald van Vollenhoven
Nature Reviews. Rheumatology|February 1, 2019
Treat-to-target in rheumatoid arthritis - are we there yet?Ronald van Vollenhoven
Nature Reviews. Rheumatology|January 15, 2016
Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatmentRonald van Vollenhoven
Lupus Science & Medicine|February 26, 2020
String of successful trials in SLE: have we cracked the code?Ronald van Vollenhoven
Arthritis & Rheumatology (Hoboken, N.J.)|September 15, 2025
"Negative" finding supports two-hit model: comment on the article by Kroese et alRonald van Vollenhoven
Arthritis and Rheumatism|August 6, 2005
Dehydroepiandrosterone versus placebo for Sjögren's syndrome: comment on the article by Pillemer et alRonald van Vollenhoven
Lancet (London, England)|May 29, 2026
Targeting CD40 with dapirolizumab pegol: a new treatment for systemic lupus erythematosusRonald van Vollenhoven
Annals of the Rheumatic Diseases|April 30, 2013
Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examplesBernard Combe, Ronald van Vollenhoven
Lupus Science & Medicine|November 8, 2014
Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issueJill Buyon, Ronald van Vollenhoven
Clinical and Experimental Rheumatology|October 17, 2013
New drugs in systemic lupus erythematosus: when to start and when to stopMarta Mosca, Ronald van Vollenhoven
Pageof 16